Braveheart Bio, Inc. BRVE · SEC Filings

website

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy...

Price19.46

Market Cap1.37 B

Float...

CountryUS

SectorHealthcare

ExchangeNASDAQ

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

TYPE

HEADLINE

FILED AT

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Sep 8, 2026

News

TYPE

HEADLINE

FILED AT

8-K

Hengrui Pharma and Braveheart Bio Present Positive 52-Week Phase 2 Data for HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at AHA 2026

Nov 6, 2026

8-K

Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update

Sep 8, 2026

8-K

Braveheart Bio, Inc. Files Amended Certificate of Incorporation and Bylaws in Connection with IPO

Aug 7, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B4

Form 424B4 - Prospectus [Rule 424(b)(4)]

Aug 6, 2026

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 6, 2026

S-1MEF

OFFERING

Aug 5, 2026

8-A12B

Form 8-A12B - Registration of securities [Section 12(b)]

Aug 3, 2026

S-1/A

OFFERING - IPO | Bank: Goldman Sachs & Co. LLC; Jefferies; TD Cowen; Stifel; Cantor

Jul 30, 2026

S-1

Form S-1 - General form for registration of securities under the Securities Act of 1933

Jul 14, 2026

DRS/A

Form DRS/A - Draft Registration Statement: [Amend]

Jun 8, 2026

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G

NEWJiangsu Hengrui Pharmaceuticals Co., Ltd. (Filed by)

Nov 9, 2026

SCHEDULE 13G

FMR LLC (Filed by)

Nov 5, 2026

SCHEDULE 13D/A

ORBIMED ADVISORS LLC (Filed by)

Sep 10, 2026

SCHEDULE 13D

ORBIMED ADVISORS LLC (Filed by)

Aug 18, 2026

Agarwala Vineeta (Reporting)

Aug 14, 2026

SCHEDULE 13D

AH Bio Fund IV, L.P. (Filed by)

Aug 14, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Aug 6, 2026